Identification of candidate microRNA biomarkers in diabetic nephropathy: a meta-analysis of profiling studies

Gholaminejad, Alieh; Tehrani, Hossein Abdul; Fesharaki, Mohammad Gholami

doi:10.1007/s40620-018-0511-5

Cited by 56 publications

(51 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diagnostic significance of circulating miRNAs in systemic lupus erythematosus miR-21 originated from chromosome 17q23.2 immediately to the vacuole membrane protein 1 gene and played an important role in regulating cell differentiation and proliferation [51][52]. Furthermore, miR-21 was considered as a promising biomarker of many diseases [53][54][55]. Also, previous studies suggested that miR-21 regulated aberrant responses of T cells of SLE [56][57], modulation of miR-21 expressions might restore the function of Treg cells and in turn reverse the clinical manifestations of SLE [19].…”

Section: Discussionmentioning

confidence: 99%

Diagnostic significance of circulating miRNAs in systemic lupus erythematosus

et al. 2019

View full text Add to dashboard Cite

BackgroundIn recent years, many studies focused on the association between the microRNAs (miR-NAs) and the risk of systemic lupus erythematosus (SLE), especially miRNA-21 (miR-21). We aimed to investigate the role of circulating miRNAs, especially the miR-21, as a biomarker in detecting SLE. MethodsWe searched PubMed, EMBASE, the Cochrane Central Register of Controlled Trials, and China National Knowledge Infrastructure through Mar 3th, 2019. We performed this metaanalysis in a fixed/random-effect model using Meta-disc 1.4 and STATA 15.1. ResultsA total of 17 relevant studies were eligible to analyze pooled accuracy. The overall performance of total mixed miRNAs (TmiRs) detection was: pooled sensitivity, 0.71 (95% confidence interval [CI], 0.69 to 0.72); pooled specificity, 0.81 (95%CI, 0.79 to 0.83); and area under the summary receiver operating characteristic curves value (SROC), 0.8797. The miR-21 detection was: pooled sensitivity, 0.68 (95%CI, 0.62 to 0.74); pooled specificity, 0.77 (95%CI, 0.69 to 0.84); and SROC, 0.8281. The meta-regression analysis showed that the type of samples was the sources of heterogeneity. The subgroup analysis suggested that detection in plasma group had the largest AUC of SROC in all the subgroups: pooled sensitivity, 0.8 (95%CI, 0.78 to 0.82); pooled specificity, 0.83 (95%CI, 0.8 to 0.86); and SROC, 0.9068. ConclusionsOur meta-analysis demonstrated that circulating miRNAs might be potential novel biomarkers for detecting SLE, especially miR-21. Moreover, plasma is recommended as the clinical specimen for diagnostic detection.

show abstract

Section: Discussionmentioning

confidence: 99%

Diagnostic significance of circulating miRNAs in systemic lupus erythematosus

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The miR-223-3p expression appears to be affected by renal diseases as its expression was shown to be reduced in both acute and chronic kidney diseases 34,35 . miR-25-3p was also shown to be downregulated in diabetic nephropathy, suggesting an influence of renal disease on its expression 36 . Although there are no previous studies examining the relationship between miR-223-3p, miR-25-3p, and hepatic encephalopathy, the association observed here indicate that expression of these miRNAs may be affected by the severity of the liver disease.…”

Section: Variablesmentioning

confidence: 98%

MicroRNA profiles in serum samples from Acute-On-Chronic Liver Failure patients and miR-25-3p as a potential biomarker for survival prediction

Cisilotto

Amaral

Rosolen

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Acute-on-chronic liver failure (ACLF) is a condition characterized by acute decompensation of cirrhosis, associated with organ failure(s), and high short-term mortality. The microRNAs or miRNAs are small non-coding RNA molecules, stable in circulating samples such as biological fluids, and the difference in expression levels may indicate the presence, absence and/or stage of the disease. We analyzed here the miRNA profiling to identify potential diagnostic or prognostic biomarkers for ACLF. The major miRNAs discovered were validated in a cohort of patients with acute decompensation of cirrhosis grouped in no ACLF or ACLF according to EASL-CLIF definition. Relationship between serum miRNAs and variables associated with liver-damage and survival outcomes were verified to identify possible prognostic markers. Our results showed twenty altered miRNAs between no ACLF and ACLF patients, and twentyseven in patients who died in 30 days compared with who survived. In validation phase, miR-223-3p and miR-25-3p were significantly altered in ACLF patients and in those who died in 30 days. miR-223-3p and miR-25-3p expression were associated with the lowest survival in 30 days. The decrease in miR-223-3p and miR-25-3p expression was associated with the presence of ACLF and poor prognosis. Of these, miR-25-3p was independently related to ACLF and 30-day mortality. The natural history of cirrhosis is usually characterized by a long-standing compensated phase followed by a transition to the decompensated disease, identified by the occurrence of specific complications of cirrhosis, such as ascites, variceal bleeding, and hepatic encephalopathy 1. Patients with both compensated or decompensated cirrhosis are at risk of progression to acute-on-chronic liver failure (ACLF), a condition characterized by an acute deterioration of the liver function and characterized by progression to extrahepatic organ failure and high short-term mortality 2,3. Although a precise definition is still lacking, the European Association for the Study of the Liver-Chronic Liver Failure (EASL-CLIF) Consortium definition is one of the most validated criteria for ACLF in patients with cirrhosis and it is based on a modified version of SOFA score called CLIF-SOFA 2,4. According to a recently published study 5 , mortality rates in ACLF patients are 25.5% and 40% in 28 and 90 days of admission, respectively. Therefore, searching for new biomarkers associated with the presence of ACLF and prognosis of patients with acute decompensation of cirrhosis may improve clinical decision and help to implement risk-adapted treatment strategies. In recent years, miRNAs have been studied as promising biomarkers for the diagnosis and prognostic in many clinical scenarios 6-8 , including liver diseases 9. The miRNAs are a group of small non-coding RNAs, with approximately 22 nucleotides, which post-transcriptionally regulate gene expression

show abstract

“…Guo et al [18] expounded that upregulated miR-29c increased the expression of inflammatory cytokines and promoted the progress of DN in DN patients. A meta-analysis on the miRNA expression profile in DN revealed downreglulation of miR-34c in at least two studies [19]. Recent studies observed that miR-34c inhibited HG-induced cell death in podocytes [20] and suppressed inflammasome activity in astrocytes, microglia, and neurons [21].…”

Section: Introductionmentioning

confidence: 99%

Long Non-Coding RNA NEAT1 Regulates Pyroptosis in Diabetic Nephropathy via Mediating the miR-34c/NLRP3 Axis

Zhan¹,

Huang²,

Huang³

et al. 2020

Kidney Blood Press Res

View full text Add to dashboard Cite

Introduction: Diabetic nephropathy (DN) is a serious complication of diabetes mellitus and is considered to be a sterile inflammatory disease. Increasing evidence suggest that pyroptosis and subsequent inflammatory response play a key role in the pathogenesis of DN. However, the underlying cellular and molecular mechanisms responsible for pyroptosis in DN are largely unknown. Methods: The rat models of DN were successfully established by single 65 mg/kg streptozotocin treatment. Glomerular mesangial cells were exposed to 30 mmol/L high glucose media for 48 h to mimic the DN environment in vitro. Gene and protein expressions were determined by quantitative real-time PCR and Western blot. Cell viability and pyroptosis were measured by MTT assay and flow cytometry analysis, respectively. The relationship between lncRNA NEAT1, miR-34c, and Nod-like receptor protein-3 (NLRP3) was confirmed by luciferase reporter assay. Results: We found that upregulation of NEAT1 was associated with the increase of pyroptosis in DN models. miR-34c, as a target gene of NEAT1, mediated the effect of NEAT1 on pyroptosis in DN by regulating the expression of NLRP3 as well as the expressions of caspase-1 and interleukin-1β. Either miR-34c inhibition or NLRP3 overexpression could reverse the accentuation of pyroptosis and inflammation by sh-NEAT1 transfection in the in vitro model of DN. Conclusions: Our findings suggested NEAT1 and its target gene miR-34c regulated cell pyroptosis via mediating NLRP3 in DN, providing new insights into understanding the molecular mechanisms of pyroptosis in the pathogenesis of DN.

show abstract

Identification of candidate microRNA biomarkers in diabetic nephropathy: a meta-analysis of profiling studies

Abstract: Five highly significant and consistently dysregulated miRNAs were identified, and future studies should focus on discovering their potential effect on DN and their clinical value as DN biomarkers and therapeutic mediators.

Cited by 56 publications

References 87 publications

Diagnostic significance of circulating miRNAs in systemic lupus erythematosus

Diagnostic significance of circulating miRNAs in systemic lupus erythematosus

MicroRNA profiles in serum samples from Acute-On-Chronic Liver Failure patients and miR-25-3p as a potential biomarker for survival prediction

Long Non-Coding RNA NEAT1 Regulates Pyroptosis in Diabetic Nephropathy via Mediating the miR-34c/NLRP3 Axis

Contact Info

Product

Resources

About